Orelabrutinib
- Generic Name
- Orelabrutinib
- Drug Type
- Small Molecule
- Chemical Formula
- C26H25N3O3
- CAS Number
- 1655504-04-3
- Unique Ingredient Identifier
- WJA5UO9E10
- Background
Orelabrutinib is under investigation in clinical trial NCT04305197 (A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)).
- Indication
⑴既往至少接受过一种治疗的成人套细胞淋巴瘤（MCL）患者。
⑵既往至少接受过一种治疗的成人慢性淋巴细胞白血病（CLL）/小淋巴细胞淋巴瘤（SLL）患者。
A Retrospective Study of Newly-diagnosed PCNSL Treated With a Methotrexate (MTX) and Orelabrutinib-based Regimen
- Conditions
- Primary Central Nervous System Lymphoma
- Interventions
- First Posted Date
- 2023-11-03
- Last Posted Date
- 2023-11-03
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT06115824
- Locations
- 🇨🇳
Department of Hematology, Huashan Hospital, Fudan University, Shanghai, China
Efficacy and Safety of Orelabrutinib Plus Lenalidomide and Rituximab (R2) Compared to Placebo Plus R2 in r/r Marginal Zone Lymphoma
- Conditions
- Relapsed/Refractory Marginal Zone Lymphoma
- Interventions
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 324
- Registration Number
- NCT06082102
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Auhui, China
🇨🇳Beijing Tongren Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
An Ambispective Cohort Study of Orelabrutinib in Combination With Standard Treatment Regimen for Untreated DLBCL
- Conditions
- Lymphoma, Large B-Cell, Diffuse Neoplasms by Histologic Type
- Interventions
- First Posted Date
- 2023-08-29
- Last Posted Date
- 2023-08-29
- Target Recruit Count
- 81
- Registration Number
- NCT06015464
- Locations
- 🇨🇳
Hematological Department, People's Hospital of Jiangsu Province, Nanjing, Jiangsu, China
Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia
- Conditions
- Chronic Primary Immune Thrombocytopenia (ITP)
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 195
- Registration Number
- NCT06004856
- Locations
- 🇨🇳
The first affiliated hospital of bengbu medical college, Bengbu, Anhui, China
🇨🇳The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Beijing CHAO-YANG Hospital Capital Medcal University, Beijing, Beijing, China
Evaluating Different Doses of Orelabrutinib in MCL
- Conditions
- Mantle Cell Lymphoma
- Interventions
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- InnoCare Pharma Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT05978739
- Locations
- 🇨🇳
The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
🇨🇳Sun Yat-sen University Cancer Center, Guangdong, Guangzhou, China
🇨🇳Peking University Third Hospital, Beijing, Beijing, China
Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System Involvement
- Conditions
- CNS Lymphoma
- Interventions
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2023-09-05
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 25
- Registration Number
- NCT05926427
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Phase IV Observational Study of Orelabrutinib in the Treatment of Chronic Lymphocytic Leukemia/Small Cell Lymphoma
- Conditions
- CLL/SLL
- First Posted Date
- 2023-06-27
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Wang Xin
- Target Recruit Count
- 20
- Registration Number
- NCT05920668
- Locations
- 🇨🇳
Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China
Clinical Study of Orelabrutinib Combined With BG Regimen First-line Treatment of CLL/SLL
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2023-06-26
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 24
- Registration Number
- NCT05918276
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳The Central Hospital Of Wuan, Wuhan, Hubei, China
Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients
- Conditions
- Diffuse Large B Cell Lymphoma
- Interventions
- Drug: Pro-miniCHOP-like regimenDrug: R-miniCHOP-like regimen
- First Posted Date
- 2023-04-12
- Last Posted Date
- 2023-04-20
- Lead Sponsor
- The First Affiliated Hospital of Soochow University
- Target Recruit Count
- 35
- Registration Number
- NCT05809180
- Locations
- 🇨🇳
the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- First Posted Date
- 2023-03-27
- Last Posted Date
- 2023-03-27
- Target Recruit Count
- 60
- Registration Number
- NCT05784987
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.